These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1233896)

  • 1. [Psychological changes in patients with Parkinson's disease during treatment with L-Dopa. Interpretation and comprehension of the observed phenomena].
    Fau R; Perret J; Israël L; Ohlmann T
    Ann Med Psychol (Paris); 1975 May; 1(5):670-83. PubMed ID: 1233896
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
    Jacobi P; Schneider E; Gundelsheimer W; Fischer PA
    Nervenarzt; 1974 Nov; 45(11):588-94. PubMed ID: 4453348
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa and executive performance in Parkinson's disease: a randomized study.
    Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
    J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute effects of L-dopa on event-related desynchronization in Parkinson's disease.
    Magnani G; Cursi M; Leocani L; Volonté MA; Comi G
    Neurol Sci; 2002 Sep; 23(3):91-7. PubMed ID: 12391492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary factors in the management of Parkinson's disease.
    Kempster PA; Wahlqvist ML
    Nutr Rev; 1994 Feb; 52(2 Pt 1):51-8. PubMed ID: 8183469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
    Garcia-Borreguero D; Caminero AB; De La Llave Y; Larrosa O; Barrio S; Granizo JJ; Pareja JA
    Mov Disord; 2002 Sep; 17(5):934-41. PubMed ID: 12360542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.
    Marini P; Ramat S; Ginestroni A; Paganini M
    Neurol Sci; 2003 Oct; 24(3):184-5. PubMed ID: 14598078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 18. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years].
    Indo T; Takahashi A
    Rinsho Shinkeigaku; 1987 Nov; 27(11):1419-22. PubMed ID: 3447802
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
    Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
    Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.